OCMS Bio

Executive Summary

OCMS Bio is a San Diego-based biotech company leveraging AI-driven drug discovery combined with function-first antibody selection to accelerate the development of antibody therapeutics. Founded in 2018, the company aims to overcome traditional bottlenecks in antibody discovery by integrating computational design with functional screening, potentially reducing timelines and improving success rates. Despite being in the pre-clinical stage with no disclosed funding or public pipeline, its platform targets faster, better breakthroughs in the competitive AI drug discovery landscape. The company's private status limits visibility, but its differentiated approach positions it for potential growth as it progresses toward clinical development.

Upcoming Catalysts (preview)

• TBDSeries A Fundraising Announcement60% success
• TBDPre-clinical Proof-of-Concept Data Release50% success